نداء الوطن
نداء الوطن
Ready to play
Ready to play
Members of the "Strong Republic" bloc have proposed a law to regulate the registration, importation, and circulation of biosimilars in Lebanon. The aim is to protect citizens' health and ensure the quality and safety of medications used to treat serious and complex diseases such as cancer and autoimmune disorders. This legislation seeks to establish a legal framework aligned with international standards, emphasizing the importance of assessing the quality, safety, and efficacy of these drugs, and requiring thorough scientific evaluation to verify their similarity to reference products. It also proposes the creation of a public electronic registry of licensed medicines, enhances transparency through oversight mechanisms that can suspend or revoke licenses if risks emerge, and enforces penalties for violations. The law underscores that patient safety demands clear rules to ensure that medicines reaching patients are safe and effective, manufactured according to the highest quality standards. It specifically emphasizes zero tolerance for the entry of potentially ineffective or harmful drugs, especially those originating from unreliable sources, acknowledging the increase over recent years of biosimilars that do not meet safety standards. The deputies conclude their appeal by urging the swift enactment of this law to safeguard medication safety and protect the health of Lebanese citizens.
Notice: This Is an AI-Generated Summary
Comments (0)